Navigation Links
S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
Date:5/4/2011

and has now completed Phase 2 trials for MF.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, SB939, is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. More information about S*BIO can be found at www.sbio.com.S*BIO Pte Ltd:Russo Partners:Hew Yin Chin, Ph.D.

Tony Russo +1 212-845-4251Associate Director, Corporate Development

Tony.Russo@russopartnersllc.com Tel: +65 6827 5000 (Singapore)

Andreas Marathovouniotis +1 212-845-4235yinchin_hew@sbio.com

Andreas.Marathis@russopartnersllc.com
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
3. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe’s ... expertise to the Los Angeles County clinics including ... procedures are now being offered at all Healthpointe ... County, and San Bernardino County. , As ... neurons send electrical impulses throughout the body ...
(Date:5/29/2015)... May 29, 2015 The annual aesthetic meeting, ... (ASAPS), was held in Montreal from May 14-19th. This ... aesthetic professionals from around the world; dedicating itself exclusively to ... many renowned plastic surgeons to attend this year’s ... six-day event, Dr. Vitenas was given the honor of sitting ...
(Date:5/29/2015)... The FSH Society , the ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy ... FSHD Trial Preparedness Workshop. The Workshop, being held ... Rochester Medical Center in Rochester, New York, will ... world, including representatives from industry, the Food and ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The popular ... of their rewards based L-Style Select Program that gives ... program is limited to only 100 members per year, ... work one on one with fitness experts at Nuretix ... cost to them provided that they attain and maintain ...
(Date:5/29/2015)... NEW YORK (PRWEB) May 29, 2015 ... Medical Center has found that a urine test ... cancer with 92 percent accuracy. Dr. James McKiernan ... 2015 Annual Meeting Press Event. , Dr. ... John K. Lattimer Professor and chair of the ...
Breaking Medicine News(10 mins):Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 2Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 3Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 3
... ... before and after photos , ... 9, 2010 -- HCG True Diet offers new HCG Diet before and after photos and revamped ... navigation bar at the left hand of the site. The photos are taken of a ...
... HealthDay Reporter , THURSDAY, July 8 (HealthDay News) -- The ... smoke has slowed significantly, following dramatic drops starting in the ... percent of high school students still smoke, making it impossible ... among teens to 16 percent or less, the U.S. Centers ...
... ... career opportunities for ambitious professionals. , ... (PRWeb UK) July 9, 2010 -- HCL International, the leading global health and social ... GPs and social workers interested in working in Australia, at an invitation-only ...
... ... discovered a different kind of healing through writing down her emotions , ... Honolulu, HI (Vocus) July 9, 2010 -- She ... the release of Finally, it’s my time!, her new book made available through Xlibris, author ...
... ... new ways to make extra cash without having to spend big dollars. ... and beauty”. While most people cut back on certain luxuries during hard ... the recession. Youthful Trends is an innovative cosmetic company that is banking ...
... obese children have a 40 percent higher risk of ... obese have a 30 percent higher risk of GERD ... Permanente study published online in the International Journal ... establishes an association between obesity and GERD in children, ...
Cached Medicine News:Health News:See New HCG Diet Before and After Photos 2Health News:Decline in U.S. Teen Smoking Rate Stalls 2Health News:Decline in U.S. Teen Smoking Rate Stalls 3Health News:HCL International: Australia a Favourite Destination for UK Social Workers and GPs 2Health News:HCL International: Australia a Favourite Destination for UK Social Workers and GPs 3Health News:Moving On With A Pen 2Health News:Natural Cosmetic Company Offers Women Entrepreneurs a New Way to Make Money in Hard Times 2Health News:Natural Cosmetic Company Offers Women Entrepreneurs a New Way to Make Money in Hard Times 3Health News:Natural Cosmetic Company Offers Women Entrepreneurs a New Way to Make Money in Hard Times 4Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 2Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 3
... unit provides a convenient reservoir of cooling water for ... an extended period of time or in a location ... cool the hot side of the thermoelectric heat pump. ... which is adequate to run the 900R for up ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Inquire...
Inquire...
Medicine Products: